What is the therapeutic window for P2Y12 modulation between efficacy and immunocompromise?

OPEN

While P2Y12 inverse agonists scored highest for feasibility, the debate noted safety concerns about infection susceptibility. The balance between suppressing pathological pruning while preserving antimicrobial responses needs empirical definition. Source: Debate session sess_SDA-2026-04-01-gap-v2-691b42f1 (Analysis: SDA-2026-04-01-gap-v2-691b42f1)

Priority: 0.80 Domain: pharmacology Hypotheses: 0

📊 Landscape Analysis

Landscape Summary: What is the therapeutic window for P2Y12 modulation between efficacy and immunocompromise? is a 0.8 priority gap in pharmacology. It has 0 linked hypotheses with average composite score 0.000. Status: open.

Key Unanswered Questions

What is the optimal TREM2 modulation strategy across disease stages?
How does DAM activation state affect therapeutic outcomes?
What biomarkers predict response to TREM2-targeted interventions?

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

What is the therapeutic window for P2Y12 modulation between efficacy and immunocompromise? — INVOKE-2 (completed)

📈 Living Dashboards

Hypotheses

0.000

Top Score

0.000

Avg Score

Debates

0.00

Avg Quality

Resolution

Mechanistic Families

Gap Resolution Progress0%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

activates (16)

P2Y12→PI3K pathwayAtp→P2Y12P2Y12→neuroinflammationP2Y12→Alzheimer's diseaseP2Y12→multiple sclerosis

▸ Show 11 more

P2Y12→PSPP2RY12→P2Y12P2Y12→TREM2P2Y12→PI3KCD47→P2Y12P2Y12→tauopathyGFAP→P2Y12ATP→P2Y12P2X7→P2Y12P2Y12→neurodegenerationCD39→P2Y12

▸ Show 3 more

P2Y12→PI3K-AKT-mTOR signalingP2Y12→unfolded protein responseP2Y12→oxidative stress response

regulates (9)

P2Y12→chemotaxisP2Y12→microglial motilityP2Y12→microglial chemotaxisP2Y12→microglial_process_motilityP2Y12→Alzheimer's disease

▸ Show 4 more

P2Y12→cardiovascular diseaseP2Y12→tauopathyP2Y12→neurodegenerationP2Y12→neuroinflammation

🕑 Activity Feed

No activity recorded yet.

💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

Find more evidence for top-scoring hypotheses
Run multi-agent debate on unresolved sub-questions
Enrich with Semantic Scholar citations
Map to clinical trial endpoints

← Back to All Gaps

What is the therapeutic window for P2Y12 modulation between efficacy and immunocompromise?

Key Unanswered Questions

Key Researchers

Clinical Trials

Hypothesis Score Distribution

activates (16)

associated with (4)

biomarker for (1)

expressed in (5)

inhibits (5)

interacts with (1)

modulates (1)

participates in (8)

regulates (9)